Monobodies as tool biologics for accelerating target validation and druggable site discovery

Despite increased investment and technological advancement, new drug approvals have not proportionally increased. Low drug approval rates, particularly for new targets, are linked to insufficient target validation at early stages. Thus, there remains a strong need for effective target validation tec...

Descripción completa

Detalles Bibliográficos
Autores principales: Akkapeddi, Padma, Teng, Kai Wen, Koide, Shohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: RSC 2021
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597423/
https://www.ncbi.nlm.nih.gov/pubmed/34820623
http://dx.doi.org/10.1039/d1md00188d

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597423/
https://www.ncbi.nlm.nih.gov/pubmed/34820623
http://dx.doi.org/10.1039/d1md00188d

Ejemplares similares